glp-1 blue cross Independence to stop covering agonists Wegovy, Ozempic as weight loss drugs in 2025 excellus bcbs glp 1 coverage

By eliminating membership fees, consultation charges, and shipping costs, the platform provides a simplified pricing structure designed to reduce barriers to treatment

alikan N et al

10.1074/jbc.M307525200 18 ChronopoulouE

All content on this site is for educational and informational purposes only, does not constitute medical advice, and does not establish any kind of patient-provider or client-professional relationship by your use of this website

Providers adjust based on your progress, side effects, and evolving needs

The three GLP-1 medications approved by the FDA to treat obesity include: Liraglutide (Saxenda/Victoza) Semaglutide (Wegovy/Ozempic/Rybelsus) Tirzepatide (Zepbound/Mounjaro) GLP-1 medications can lead to an average weight loss of 10% to 20% over 12-24 months when used alongside healthy diet and exercise changes